efficacy of Levothyroxine on pulmonary function tests in patients with subclinical hypothyroidism

Study of the efficacy of Levothyroxine on pulmonary function tests in patients with subclinical hypothyroidism in comparison with Placebo

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180811040767N1

Enrollment

Registered

2018-11-30

Start date

2018-12-11

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

subclinical hypothyroidism. Subclinical iodine-deficiency hypothyroidism

Interventions

Intervention 1: Intervention group: Name of drug :Levothyroxine 50 Micrograms Daily made in Islamic republic of Iran by Iran Hormone Company. Intervention 2: Control group: Placebo.

Eligibility

Sex/Gender

All

Age

25 Years to 55 Years

Inclusion criteria

Inclusion criteria: Diagnosis of subclinical hypothyroidism Minimum age of 25 years old Maximum age of 55 years old

Exclusion criteria

Exclusion criteria: Chronic pulmonary disease Hypertension Diabetes Chronic kidney disease Chronic heart disease Stroke Receiving heart medicine (such as amiodarone, beta-blockers and calcium blockers) Smoking cigarette or shisha Critical patients Pregnancy Goiter obesity Individuals with TSH level above 10 Individuals with a history of thoracic and abdominal surgery Patients with any systemic disease leading to myopathy

Design outcomes

Primary

Measure	Time frame
Forced expiratory volume in 1 second (FEV1). Timepoint: At the beginning of the study (before the intervention) and twelve weeks after the intervention. Method of measurement: Spirometry.;Forced vital capacity (FVC). Timepoint: At the beginning of the study (before the intervention) and twelve weeks after the intervention. Method of measurement: Spirometry.;Forced expiratory volume in 1 second / Forced vital capacity (FEV1/FVC). Timepoint: At the beginning of the study (before the intervention) and twelve weeks after the intervention. Method of measurement: Spirometry.;Peak expiratory flow rate (PEFR). Timepoint: At the beginning of the study (before the intervention) and twelve weeks after the intervention. Method of measurement: Spirometry.;Forced expiratory flow 25–75% (FEF 25–75%). Timepoint: At the beginning of the study (before the intervention) and twelve weeks after the intervention. Method of measurement: Spirometry.;Peak expiratory Flow (PEF). Timepoint: At the beginning of the study (before the intervention) and twelve weeks after the intervention. Method of measurement: Spirometry.;Diffusing capacity of the lung for carbon monoxide (DLCO). Timepoint: At the beginning of the study (before the intervention) and twelve weeks after the intervention. Method of measurement: Plethysmography.;Maximal inspiratory pressure (PIMAX). Timepoint: At the beginning of the study (before the intervention) and twelve weeks after the intervention. Method of measurement: Plethysmography.;Maximal expiratory pressure (PEMAX). Timepoint: At the beginning of the study (before the intervention) and twelve weeks after the intervention. Method of measurement: Plethysmography.;Functional Residual Capacity (FRC). Timepoint: At the beginning of the study (before the intervention) and twelve weeks after the intervention. Method of measurement: Plethysmography.;Residual Volume (RV). Timepoint: At the beginning of the study (before the intervention) and twelve weeks after the interventio	—

Measure

Time frame

Forced expiratory volume in 1 second (FEV1). Timepoint: At the beginning of the study (before the intervention) and twelve weeks after the intervention. Method of measurement: Spirometry.;Forced vital capacity (FVC). Timepoint: At the beginning of the study (before the intervention) and twelve weeks after the intervention. Method of measurement: Spirometry.;Forced expiratory volume in 1 second / Forced vital capacity (FEV1/FVC). Timepoint: At the beginning of the study (before the intervention) and twelve weeks after the intervention. Method of measurement: Spirometry.;Peak expiratory flow rate (PEFR). Timepoint: At the beginning of the study (before the intervention) and twelve weeks after the intervention. Method of measurement: Spirometry.;Forced expiratory flow 25–75% (FEF 25–75%). Timepoint: At the beginning of the study (before the intervention) and twelve weeks after the intervention. Method of measurement: Spirometry.;Peak expiratory Flow (PEF). Timepoint: At the beginning of the study (before the intervention) and twelve weeks after the intervention. Method of measurement: Spirometry.;Diffusing capacity of the lung for carbon monoxide (DLCO). Timepoint: At the beginning of the study (before the intervention) and twelve weeks after the intervention. Method of measurement: Plethysmography.;Maximal inspiratory pressure (PIMAX). Timepoint: At the beginning of the study (before the intervention) and twelve weeks after the intervention. Method of measurement: Plethysmography.;Maximal expiratory pressure (PEMAX). Timepoint: At the beginning of the study (before the intervention) and twelve weeks after the intervention. Method of measurement: Plethysmography.;Functional Residual Capacity (FRC). Timepoint: At the beginning of the study (before the intervention) and twelve weeks after the intervention. Method of measurement: Plethysmography.;Residual Volume (RV). Timepoint: At the beginning of the study (before the intervention) and twelve weeks after the interventio

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKhadijeh Kordi Tamandani

Zahedan University of Medical Sciences

ahmad4341@gmail.com+98 54 3343 3407

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026